Stem Cell Transplant with CliniMACS CD34 Reagent System
This study is for patients who need a stem cell transplant but don't have a perfectly matched donor. It uses a special machine called the CliniMACS CD34 Reagent System to prepare stem cells from a close relative. This machine separates the stem cells from other white blood cells using a special protein (CD34 antibody). The goal is to see how well the new stem cells grow (engraftment) and to check for a common complication called acute GvHD (Graft-versus-Host Disease, where the donor cells attack the patient's body). You can join if you need an allogeneic (from a donor) stem cell transplant, are between birth and 70 years old, and can sign the consent form. The study is currently unclear about its recruitment status.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 241 participants.
- What's involved
- You will have follow-up exams on days 28, 60, 100, 180, and 365 after the transplant. Health information will be collected for one year after the stem cell infusion.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for approximately one year after the stem cell infusion, with specific evaluations up to 365 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
At a glance
Conditions
NCT01189786
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Houston Methodist Hospital
Houston, Texasstudy coordinator listed
Recruiting
Texas Children's Hospital
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Robert Krance, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- For Cohort 1: the rate of primary engraftment 50 days post SCT50 days
Primary engraftment is defined as achievement of absolute neutrophil count (ANC) is greater than or equal to 500/ul for three consecutive days by day 50 post transplant. The treatment regimen will be considered clinically useful if the primary engraftment rate is at least 85%.
- For Cohort 2 (Without Conditioning) and Cohort 3 (With Conditioning): The total incidence of overall acute GvHD (greater than or equal to grade 3)100 days
The overall incidence of acute GvHD will be measured 100 days post stem cell transplant. The regimen will be considered acceptable if aGvHD greater than or equal to grade 3 rate is at least 10% or lower.